CAR T Therapy for Rare B-Cell Malignancies: Current Evidence and Future Directions

Panelists discuss how innovative treatment strategies, including immune-based and cell-directed therapies, are transforming care for patients with relapsed or refractory follicular and marginal zone lymphomas by improving long-term outcomes, enhancing safety, and prioritizing patient-centered approaches that balance efficacy, quality of life, and access to advanced, personalized treatment options.